CN106591446A - Application of cellular pathway regulation molecules as drug target and to EBOV (Ebola virus) infection diagnosis - Google Patents
Application of cellular pathway regulation molecules as drug target and to EBOV (Ebola virus) infection diagnosis Download PDFInfo
- Publication number
- CN106591446A CN106591446A CN201611117710.8A CN201611117710A CN106591446A CN 106591446 A CN106591446 A CN 106591446A CN 201611117710 A CN201611117710 A CN 201611117710A CN 106591446 A CN106591446 A CN 106591446A
- Authority
- CN
- China
- Prior art keywords
- genes
- ebov
- infection
- diagnosis
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 63
- 238000003745 diagnosis Methods 0.000 title claims abstract description 49
- 241001115402 Ebolavirus Species 0.000 title abstract description 5
- 230000033228 biological regulation Effects 0.000 title abstract description 5
- 239000003596 drug target Substances 0.000 title abstract description 5
- 230000004640 cellular pathway Effects 0.000 title abstract 3
- 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 claims abstract description 29
- 101000606129 Homo sapiens Tyrosine-protein kinase receptor TYRO3 Proteins 0.000 claims abstract description 26
- 108010014380 Autophagy-Related Protein-1 Homolog Proteins 0.000 claims abstract description 24
- 101000741087 Homo sapiens Caspase-6 Proteins 0.000 claims abstract description 24
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 claims abstract description 24
- 101001065747 Homo sapiens E3 ubiquitin-protein ligase LRSAM1 Proteins 0.000 claims abstract description 24
- 101001134216 Homo sapiens Macrophage scavenger receptor types I and II Proteins 0.000 claims abstract description 24
- 101000763003 Homo sapiens Two pore channel protein 1 Proteins 0.000 claims abstract description 24
- 101000679525 Homo sapiens Two pore channel protein 2 Proteins 0.000 claims abstract description 24
- 108050006685 Apoptosis regulator BAX Proteins 0.000 claims abstract description 23
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 claims abstract description 23
- 101000896743 Homo sapiens Anamorsin Proteins 0.000 claims abstract description 23
- 101000741014 Homo sapiens Caspase-7 Proteins 0.000 claims abstract description 23
- 101000983523 Homo sapiens Caspase-9 Proteins 0.000 claims abstract description 23
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 claims abstract description 23
- 101001018258 Homo sapiens Macrophage receptor MARCO Proteins 0.000 claims abstract description 23
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 claims abstract description 23
- 101150097381 Mtor gene Proteins 0.000 claims abstract description 23
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 claims abstract description 23
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 claims abstract description 20
- 102100039127 Tyrosine-protein kinase receptor TYRO3 Human genes 0.000 claims abstract description 20
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims abstract description 19
- 102100021697 Anamorsin Human genes 0.000 claims abstract description 18
- 102100038918 Caspase-6 Human genes 0.000 claims abstract description 18
- 102100038902 Caspase-7 Human genes 0.000 claims abstract description 18
- 102100026548 Caspase-8 Human genes 0.000 claims abstract description 18
- 102100032049 E3 ubiquitin-protein ligase LRSAM1 Human genes 0.000 claims abstract description 18
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims abstract description 18
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 claims abstract description 18
- 102100033272 Macrophage receptor MARCO Human genes 0.000 claims abstract description 18
- 102100034184 Macrophage scavenger receptor types I and II Human genes 0.000 claims abstract description 18
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims abstract description 18
- 102100040247 Tumor necrosis factor Human genes 0.000 claims abstract description 18
- 102100026736 Two pore channel protein 1 Human genes 0.000 claims abstract description 18
- 102100022609 Two pore channel protein 2 Human genes 0.000 claims abstract description 18
- 102100027308 Apoptosis regulator BAX Human genes 0.000 claims abstract description 17
- 102100026550 Caspase-9 Human genes 0.000 claims abstract description 17
- 102000007343 Hepatitis A Virus Cellular Receptor 1 Human genes 0.000 claims abstract description 17
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 claims abstract description 17
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims abstract description 17
- 102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 claims abstract description 17
- 102100039988 Serine/threonine-protein kinase ULK1 Human genes 0.000 claims abstract 6
- 230000014509 gene expression Effects 0.000 claims description 52
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 19
- 102000009565 Lysosomal-Associated Membrane Protein 2 Human genes 0.000 claims description 18
- 108010009491 Lysosomal-Associated Membrane Protein 2 Proteins 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 101150117895 LAMP2 gene Proteins 0.000 claims description 6
- 101150033527 TNF gene Proteins 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 6
- 238000001228 spectrum Methods 0.000 claims description 6
- 238000010276 construction Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 8
- 238000003759 clinical diagnosis Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 2
- 101100545004 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YSP2 gene Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 102000016956 Autophagy-Related Protein-1 Homolog Human genes 0.000 description 12
- 108091070501 miRNA Proteins 0.000 description 12
- 239000002679 microRNA Substances 0.000 description 11
- 102100036966 Dipeptidyl aminopeptidase-like protein 6 Human genes 0.000 description 8
- 102100034827 Homeobox protein Meis3 Human genes 0.000 description 8
- 101000804935 Homo sapiens Dipeptidyl aminopeptidase-like protein 6 Proteins 0.000 description 8
- 101001019059 Homo sapiens Homeobox protein Meis3 Proteins 0.000 description 8
- 101000962977 Homo sapiens Protein mab-21-like 3 Proteins 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 102100039625 Protein mab-21-like 3 Human genes 0.000 description 8
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 8
- 102100033380 Chordin Human genes 0.000 description 7
- 101000943798 Homo sapiens Chordin Proteins 0.000 description 7
- 101001002513 Homo sapiens Immunoglobulin superfamily DCC subclass member 3 Proteins 0.000 description 7
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 7
- 101000575036 Homo sapiens Putative homeobox protein Meis3-like 1 Proteins 0.000 description 7
- 101000866336 Homo sapiens Transcription factor E2F5 Proteins 0.000 description 7
- 101000866340 Homo sapiens Transcription factor E2F6 Proteins 0.000 description 7
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 7
- 102100021041 Immunoglobulin superfamily DCC subclass member 3 Human genes 0.000 description 7
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 7
- 102100031632 Transcription factor E2F5 Human genes 0.000 description 7
- 102100031631 Transcription factor E2F6 Human genes 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 108091070511 Homo sapiens let-7c stem-loop Proteins 0.000 description 6
- 108091070512 Homo sapiens let-7d stem-loop Proteins 0.000 description 6
- 108091070510 Homo sapiens let-7f-1 stem-loop Proteins 0.000 description 6
- 108091070526 Homo sapiens let-7f-2 stem-loop Proteins 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 5
- 108091070514 Homo sapiens let-7b stem-loop Proteins 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 101150047706 CASP6 gene Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 108091070521 Homo sapiens let-7a-1 stem-loop Proteins 0.000 description 4
- 108091070522 Homo sapiens let-7a-2 stem-loop Proteins 0.000 description 4
- 108091070513 Homo sapiens let-7a-3 stem-loop Proteins 0.000 description 4
- 108020004566 Transfer RNA Proteins 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 208000030820 Ebola disease Diseases 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 101710144990 Anamorsin Proteins 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 description 1
- 102000004018 Caspase 6 Human genes 0.000 description 1
- 108090000425 Caspase 6 Proteins 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102000004091 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 101150117028 GP gene Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000945963 Homo sapiens CCAAT/enhancer-binding protein beta Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 1
- 101710089357 Macrophage receptor MARCO Proteins 0.000 description 1
- 108091030146 MiRBase Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101000929430 Rattus norvegicus Epithelial discoidin domain-containing receptor 1 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 208000013222 Toxemia Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 101150010086 VP24 gene Proteins 0.000 description 1
- 101150026858 VP30 gene Proteins 0.000 description 1
- 101150077651 VP35 gene Proteins 0.000 description 1
- 101150036892 VP40 gene Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 102000055102 bcl-2-Associated X Human genes 0.000 description 1
- 108700000707 bcl-2-Associated X Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 102000006533 chordin Human genes 0.000 description 1
- 108010008846 chordin Proteins 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 108091045440 let-7a-1 stem-loop Proteins 0.000 description 1
- 108091047626 let-7a-2 stem-loop Proteins 0.000 description 1
- 108091047557 let-7a-3 stem-loop Proteins 0.000 description 1
- 108091050724 let-7b stem-loop Proteins 0.000 description 1
- 101150111214 lin-28 gene Proteins 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses application of cellular pathway regulation molecules as a drug target and to EBOV (Ebola virus) infection diagnosis. The cellular pathway regulation molecules refer to TRAF2, TP53, CASP9, RIPK3, CASP7, CIAPIN1, TNF, BAX, CASP6, TYRO3, MSR1, MARCO, HAVCR1, IRS1, LRSAM1, TPCN2, TPCN1, ULK1, AKT2, MTOR, CASP8 and LAM2. The 22 molecules can be used as key target molecules for designing anti-EBOV infection drugs and guiding strategic selection of clinical intervention means, and can also be used as biomolecule identification for clinical diagnosis of EBOV infected persons.
Description
Technical field
The present invention relates in biological technical field, cell pathway regulatory molecule is as drug target and diagnosis EBOV infection
In application.
Background technology
Ebola disease viral disease is by the Ebola virus (Ebola virus, EBOV) of Filoviridae (filoviridae)
A kind of caused acute hemorrhage sexually transmitted disease.Case fatality rate is very high, up to 50%～90%.
Ebola virus genome is sub-thread strand RNA, and about long 19kb can encoding nuclear proteins (NP) and envelope protein
7 structural protein such as (VP35, VP40, VP30, VP24), glycoprotein (GP) and RNA polymerase, wherein GP gene pairss EBOV are replicated
There are the coding and functional transcription of uniqueness.Virus is replicated in the kytoplasm of infection cell, assembling, is discharged in bud life mode.Ebola
It is viral mainly to include Zaire's type (EBOV-Z), the Sudan's type (EBOV-S), Cote d'lvoire's type (EBOV-C) and Reston type
(EBOV-R) etc., the characteristic of different subtype is different, and wherein Zaire's type virulence is most strong, and the Sudan's type takes second place, and both are to the mankind and non-
The fatality rate of people primatess is very high.Reston type and Cote d'lvoire's type are relatively low to the virulence of people, show as subclinical infection, but right
Non-human primates have mortality.
EBOV is a kind of Zoonosis virus, and its route of transmission is still not clear, generally by with mankind's close contact to infecting
The blood of animal, secretions, organ or other body fluid cause infection, and body fluid of directly contact the infected etc. can cause interpersonal
Propagate.Various non-human primate and the mankind are generally susceptible.Therefore, family member of HIV-infected people, medical worker, reviewer, angstrom
The rich staff for drawing viral prevalence scene, infection animal contactee etc. are high-risk group.
EBOV is a kind of virus of pantropic, can invade each system organ, is attached most importance to liver, spleen infringement especially.The generation of primary disease
It is relevant with the immunne response level of body.Especially phagocyte is thin by the target of virus attack first to mononuclear phagocyte system
Born of the same parents, subsequent fibroblast and endotheliocyte it is infected, vascular permeability increases, and fibrin is calm.After infection 2 days it is viral
Detect first in lung, detect in the tissue such as liver, spleen after 4 days, 6 Tian Hou body tissues can detect.
Many researchs with regard to pathogenicity at present are all carried out in animal model and experiment in vitro, and with regard to people
The correlational study of precursor virus infection is few.Each stage of virus infection body, from cell entry cell, partial copy, propagation (disease
Toxemia), in the target organ breeding, Rehabilitation (but still band poison) or dead, there is the mutual restriction of two kinds of factors：Virus
Infection and host body response and defence.Research pathogenesis and Immune escaping mechanism of the EBOV to the mankind, and then according to these
Committed step, determines modulation site, researches and develops medicine, for the Synthetical prevention of ebola hemorrhagic fever has important meaning
Justice.Meanwhile, the response feature of human infection EBOV is studied, the molecular marker of infection and prognosis characterizations is found, it is fast for setting up
Fast diagnostic method, set up timely and effective intervention stratege theoretical foundation can be provided.
The content of the invention
The technical problem to be solved is how to diagnose EBOV infection and how to design treatment and/or prevent EBOV
The drug target of infection.
For solve above-mentioned technical problem, present invention firstly provides following R1)-R4) in arbitrary application：
R1) G1 is preparing treatment and/or is preventing the application in EBOV infection products as target spot；
R2) G1 is being treated and/or is being prevented the application in EBOV infection as target spot；
R3) detect application of the system of the G1 expressions in diagnosis or auxiliary diagnosis EBOV infection product is prepared；
R4) detect application of the system of the G1 expressions in diagnosis or the infection of auxiliary diagnosis EBOV；
The G1 be TRAF2 genes, TP53 genes, CASP9 genes, RIPK3 genes, CASP7 genes, CIAPIN1 genes,
Tnf gene, BAX genes, CASP6 genes, TYRO3 genes, MSR1 genes, MARCO genes, HAVCR1 genes, IRS1 genes,
LRSAM1 genes, TPCN2 genes, TPCN1 genes, ULK1 genes, AKT2 genes, MTOR genes, CASP8 genes and/or LAMP2
Gene.
In above-mentioned application, the system of the detection G1 expressions can be to detect the G1 using method of the prior art
Reagent and/or instrument needed for expression, reagent as described in being detected using high-flux sequence needed for G1 expressions and/or
Instrument, or using the reagent and/or instrument needed for G1 expressions described in quantitative PCR detection, or hybridize skill using northern
Art detects the reagent and/or instrument needed for the G1 expressions, or using needed for G1 expressions described in genechip detection
Reagent and/or instrument.
In above-mentioned application, the high-flux sequence can be carried out using Illumina microarray datasets.
In above-mentioned application, the system of the detection G1 expressions may also include data handling system, the data processing
System is used for analyzing the result that method of the prior art is directly obtained, and determines the expression of the G1.The data processing
System can be software and/or module.
For solve above-mentioned technical problem, present invention also offers following M1)-M4) in arbitrary application：
M1) P1 is preparing treatment and/or is preventing the application in EBOV infection products as target spot；
M2) P1 is being treated and/or is being prevented the application in EBOV infection as target spot；
M3) detect application of the system of the P1 contents in diagnosis or auxiliary diagnosis EBOV infection product is prepared；
M4) detect application of the system of the P1 contents in diagnosis or the infection of auxiliary diagnosis EBOV；
The P1 be TRAF2, TP53, CASP9, RIPK3, CASP7, CIAPIN1, TNF, BAX, CASP6, TYRO3,
MSR1, MARCO, HAVCR1, IRS1, LRSAM1, TPCN2, TPCN1, ULK1, AKT2, MTOR, CASP8 and/or LAMP2 albumen
Matter.
In above-mentioned application, the system of the detection P1 contents can be to detect the P1 contents using method of the prior art
Required reagent and/or instrument, the reagent and/or instrument needed for using mass spectrum or its P1 content as described in correlation technique detection,
Or using the reagent and/or instrument needed for P1 contents described in immuning hybridization technology for detection, or the P1 is detected using elisa technique
Reagent and/or instrument needed for content, or using the reagent and/or instrument needed for P1 contents described in protein chip or detection paper
Device.
To solve above-mentioned technical problem, present invention also offers following N1) or application N2)：
N1) using above-mentioned G1 as system used in the diagnosis of EBOV infection marks or auxiliary diagnosis EBOV infection method
In following a1) or a2) in application：
A1 diagnosis or auxiliary diagnosis EBOV infection product) are prepared；
A2) diagnosis or the infection of auxiliary diagnosis EBOV；
N2) using above-mentioned P1 as system used in the diagnosis of EBOV infection marks or auxiliary diagnosis EBOV infection method
In above-mentioned a1) or a2) in application.
It is described using above-mentioned G1 as EBOV infect mark diagnosis or auxiliary diagnosis EBOV infection method in used be
System can be the system of detection G1 expressions mentioned above.
To solve above-mentioned technical problem, present invention also offers following W1) or product W2)：
W1 EBOV infection products) are treated and/or prevent, the product is with above-mentioned G1 as target spot；
W2 EBOV infection products) are treated and/or prevent, the product is with above-mentioned P1 as target spot.
To solve above-mentioned technical problem, present invention also offers following X1) or product X2)：
X1) diagnosis or auxiliary diagnosis EBOV infection product, are the system for detecting above-mentioned G1 expressions；
X2) diagnosis or auxiliary diagnosis EBOV infection product, are the system for detecting above-mentioned P1 contents.
To solve above-mentioned technical problem, present invention also offers the EBOV infection relevant molecular characteristics spectrums of non-diagnostic purpose
Construction method.
The construction method of the EBOV infection relevant molecular characteristics spectrums of non-diagnostic purpose provided by the present invention includes：It is right respectively
RNA or protein in EBOV infected groups and non-EBOV infected groups blood carries out quantitative analyses, obtains EBOV according to analysis result
Virus load relevant molecular characteristics are composed；The EBOV virus loads relevant molecular characteristics spectrum is above-mentioned G1 or above-mentioned P1.
In said method, the RNA or protein in EBOV infected groups and non-EBOV infected groups blood is carried out quantitatively
Analysis specifically may also include：RNA or protein in purification EBOV infected groups and non-EBOV infected groups blood, using Illumina
Microarray dataset detects the content of RNA or protein.
RNA or protein in the purification EBOV infected groups and non-EBOV infected groups blood is using with Oligo
(dT) magnetic bead is carried out.
The content of the utilization Illumina microarray datasets detection RNA or protein may include：By RNA fragments after purification
Change, and as template reverse transcription synthetic double chain cDNA：End is carried out to double-strand cDNA and repairs polishing so as to 5 ' end phosphoric acid
Change, 3 ' ends add " A "；Double-strand cDNA joint with 3 ' dTMP ends is connected in sequence measuring joints, is expanded by PCR, using AMPure
XP enrichment with magnetic bead purification joint products, obtain library；The library for building is carried out double ends to survey with Illumina microarray datasets
Sequence, detects the content of RNA or protein in sample to be tested.
Above, the G1 expressions can be the expression of G1 described in blood.The P1 contents can be in blood
The content of the P1.
Above, the treatment and/or prevention EBOV infection product can be medicine or vaccine.The diagnosis or auxiliary diagnosis
EBOV infection product can be medicine and/or health equipment, such as reagent, reagent paper, material or instrument.
In actual applications, can by compare TRAF2, TP53, CASP9, RIPK3, CASP7, CIAPIN1, TNF, BAX,
CASP6, TYRO3, MSR1, MARCO, HAVCR1, IRS1, LRSAM1, TPCN2, TPCN1, ULK1, AKT2 and MTOR and
Expressions of the CASP8 and LAMP2 in object to be measured with non-EBOV the infected's blood is judging whether object to be measured is EBOV
The infected.Specific criterion is as follows：As the TRAF2 of object to be measured, TP53, CASP9, RIPK3, CASP7, CIAPIN1,
TNF, BAX, CASP6, TYRO3, MSR1, MARCO, HAVCR1, IRS1, LRSAM1, TPCN2, TPCN1, ULK1, AKT2 and MTOR
In the expression of at least one higher than 2 times or CASP8 and LAMP2 of the corresponding molecule of non-EBOV the infected at least one
Expression less than the corresponding molecule of non-EBOV the infected 1/2, the object to be measured be candidate be EBOV the infected；As described
The TRAF2 of object to be measured, TP53, CASP9, RIPK3, CASP7, CIAPIN1, TNF, BAX, CASP6, TYRO3, MSR1,
The expression of MARCO, HAVCR1, IRS1, LRSAM1, TPCN2, TPCN1, ULK1, AKT2 and MTOR is not higher than non-EBOV
2 times of the corresponding molecule of the infected and the expression of CASP8 and LAMP2 is not less than the 1/2 of the corresponding molecule of non-EBOV the infected,
The object to be measured is or candidate is non-EBOV the infected.
The present invention is by the non-EBOV the infected of comparison and the difference expression gene of EBOV the infected, and is divided by dependency
Analysis, finds the differential expression molecule (r related to EBOV virus loads in EBOV the infected's blood2>0.64,p<0.01)——
TRAF2、TP53、CASP9、RIPK3、CASP7、CIAPIN1、TNF、BAX、CASP6、TYRO3、MSR1、MARCO、HAVCR1、
IRS1, LRSAM1, TPCN2, TPCN1, ULK1, AKT2 and MTOR and CASP8 and LAMP2, this 22 molecules are infected in EBOV
The high expression of blood samples of patients cell can the efficient phagocytic virus granule of inducing host cell, but but cannot quickly remove virus,
So that virus is successfully, reproduced in the cell, and the virus for replicating is spread in vivo by necrosis and apoptosis.These result tables
The key molecule of bright these host cells participates in and decides the destiny of EBOV infected patient body cells, participates in EBOV in body
In course of infection, can be used as key target molecule, the design and guidance for anti-Ebola virus infection medicine are clinical dry
The policy selection of pre- means, is also used as biomolecule mark, for the clinical diagnosises of EBOV the infected.
Specific embodiment
The present invention is further described in detail with reference to specific embodiment, the embodiment for being given is only for explaining
The bright present invention, rather than in order to limit the scope of the present invention.
Experimental technique in following embodiments, if no special instructions, is conventional method.
In following embodiments, material used, reagent etc., if no special instructions, commercially obtain.
Embodiment 1, the host's key molecule for participating in EBOV infected patient cell regulate and controls
Total serum IgE is extracted from EBOV the infected with non-EBOV the infected's whole blood, it is pure with the absorption of the magnetic bead with Oligo (dT)
Change the mRNA in total serum IgE, in a heated condition by mRNA fragmentations, and as template reverse transcription synthetic double chain cDNA.To double
Chain cDNA carries out end and repairs polishing so as to 5 ' end phosphorylations, and 3 ' ends add " A ".Double-strand cDNA joint with 3 ' dTMP ends is connected
To in sequence measuring joints, expanded by PCR, using AMPure XP enrichment with magnetic bead purification joint products, by PCR reaction identification texts
Storehouse.The library for building is carried out into double end sequencings with Illumina microarray datasets.Filter what sequencing was produced using perl script
Joint sequence, two ends low quality sequence (Q in initial data<=20 base number accounts for more than the 50% of whole piece reads sequence
Row), Sequences of Low Complexity.
Valid data are compared into people with reference on genome using Tophat softwares, Cutfflinks software combinations compare knot
Really, differential expression of the EBOV the infected (n=22) compared with non-EBOV the infected (n=10) is drawn by Cutffdiff softwares
Gene, further by correlation analysiss, finds to infect the biomolecule for determining that host cell destiny is relevant with EBOV.As a result show
Show, 22 host's key molecules regulate and control closely related (p with the caused cell pathway of EBOV infection<0.0001, differential expression multiple
>2；Except TYRO3, the p value of TYRO3 is for 0.0024), this 22 molecules are respectively：Apoptosis correlation molecule TNF, TP53,
CASP9, CASP7, BAX, CASP6 and CASP8；Necrocytosiss correlation molecule TNF, TRAF2, CIAPIN1 and RIPK3；Cell is gulped down
Bite associated receptor TYRO3, MSR1, MARCO, HAVCR1, TPCN2 and TPCN1；Cell autophagy correlation molecule IRS1, AKT2,
TP53, MTOR, ULK1, LRSAM1 and LAMP2；Wherein, except CASP8 and LAMP2 are presented significant table in EBOV the infected
Outer up to lowering, other molecules occur significant up-regulated in EBOV the infected, and concrete outcome as shown in table 1, shows this
22 molecules can be identified as biomolecule, for the clinical diagnosises of EBOV the infected.
Table 1 determines the key biological molecule of EBOV virus host cells infected destiny
Note：22 molecules are listed in table 1 in EBOV the infected relative to differential expression multiple in non-EBOV the infected
(median FKPM values) and Variant statistical analysis result (P values).Wherein, TRAF2 is TNF receptor associated
The abbreviation of factor 2, abbreviations of the TP53 for tumor protein p53；Abbreviations of the CASP9 for caspase 9；RIPK3 is
The abbreviation of receptor-interacting serine-threonine kinase 3；Abbreviations of the CASP7 for caspase 7；
Abbreviations of the CIAPIN1 for cytokine induced apoptosis inhibitor 1；TNF is tumor necrosis
The abbreviation of factor；Abbreviations of the BAX for BCL2 associated X；Abbreviations of the CASP6 for caspase 6；TYRO3 is TYRO3
The abbreviation of protein tyrosine kinase 3；Abbreviations of the MSR1 for macrophage scavenger receptor 1；
Abbreviations of the MARCO for macrophage receptor with collagenous structure；HAVCR1 is hepatitis
The abbreviation of A virus cellular receptor 1；Abbreviations of the IRS1 for insulin receptor substrate 1；
Abbreviations of the LRSAM1 for leucine rich repeat and sterile alpha motif containing 1；TPCN2
For the abbreviation of two pore segment channel 2；Abbreviations of the TPCN1 for two pore segment channel 1；
Abbreviations of the ULK1 for unc-51 like autophagy activating kinase 1；AKT2 is AKT serine/
The abbreviation of threonine kinase 2；Abbreviations of the MTOR for mechanistic target of rapamycin；CASP8 is
The abbreviation of caspase 8；Abbreviations of the LAMP2 for lysosomal-associated membrane protein 2.
In actual applications, can by compare TRAF2, TP53, CASP9, RIPK3, CASP7, CIAPIN1, TNF, BAX,
CASP6, TYRO3, MSR1, MARCO, HAVCR1, IRS1, LRSAM1, TPCN2, TPCN1, ULK1, AKT2 and MTOR and
The expression of CASP8, LAMP2 in object to be measured with non-EBOV the infected's blood is come whether judge object to be measured be EBOV senses
Dye person.Specifically, the criterion for being obtained according to the above results is as follows：As the TRAF2 of object to be measured, TP53, CASP9,
RIPK3、CASP7、CIAPIN1、TNF、BAX、CASP6、TYRO3、MSR1、MARCO、HAVCR1、IRS1、LRSAM1、TPCN2、
In TPCN1, ULK1, AKT2 and MTOR the expression of at least one higher than 2 times of the corresponding molecule of non-EBOV the infected or
The expression of at least one less than the corresponding molecule of non-EBOV the infected 1/2 in CASP8 and LAMP2, the object to be measured are doubted
Like EBOV the infected；As the TRAF2 of object to be measured, TP53, CASP9, RIPK3, CASP7, CIAPIN1, TNF, BAX, CASP6,
The expression of TYRO3, MSR1, MARCO, HAVCR1, IRS1, LRSAM1, TPCN2, TPCN1, ULK1, AKT2 and MTOR is not
Higher than 2 times of the corresponding molecule of non-EBOV the infected and the expression of CASP8 and LAMP2 to be not less than non-EBOV the infected corresponding
The 1/2 of molecule, the object to be measured are non-EBOV the infected.
TRAF2、TP53、CASP9、RIPK3、CASP7、CIAPIN1、TNF、BAX、CASP6、TYRO3、MSR1、MARCO、
HAVCR1, IRS1, LRSAM1, TPCN2, TPCN1, ULK1, AKT2 and MTOR and CASP8 and LAMP2 this 22 molecules exist
The high expression of EBOV infected patient blood cells can the efficient phagocytic virus granule of inducing host cell, but but cannot be quickly clear
Except virus so that virus is successfully, reproduced in the cell, and the virus for replicating is spread in vivo by necrosis and apoptosis.These
As a result show that the key molecule of these host cells participates in and decide the destiny of EBOV infected patient body cells, participate in EBOV
Course of infection in body, can be as key target molecule, for the design and guidance of anti-Ebola virus infection medicine
The policy selection of clinical intervention means.
The present invention also have chosen the blood sample of 6 non-EBOV the infecteds and 20 EBOV the infecteds in addition, using fixed
Amount RT-PCR technology have detected the table of RIPK3 genes and Casp6 genes in this 22 molecules in these object of study blood
Up to level.Wherein, the primer sequence of RIPK3 genes be 5 '-CGGGCGCAACATAGGAAGT-3 ' (sequence 1) and 5 '-
CTTCTAGGCGCAGCACGAAT-3 ' (sequence 2), the primer sequence of Casp6 genes is 5'-
GTCAACTGTTAGCCACGCAGAT-3'(sequences are 3) with 5'-AACCAGGCTGTGACACTTGTCT-3'(sequences 4).
As a result find, the expression of RIPK3 genes and Casp6 genes in EBOV the infected's blood is substantially less than non-
In EBOV the infected's blood, corresponding Cytokine Expression Level (table 2), shows, RIPK3 and Casp6 can be auxiliary as mark
Diagnosis EBOV the infected is helped, key target molecule is also used as, design for anti-Ebola virus infection medicine and is referred to
Lead the policy selection of clinical intervention means.
Table 2, cell death associated gene (RIPK3, CASP6) RT-PCR experimental results
Embodiment 2, the tiny RNA s (sRNAs) for participating in EBOV infection damage regulation and control
Total serum IgE is extracted from EBOV the infected with non-EBOV the infected's whole blood, using 15% denaturing polyacrylamide gel
Electrophoretic techniquess (PAGE) separate small fragment (15-30nt) RNA from total serum IgE, after purification to detached small fragment RNA connection 3 ' and
5 ' end connectors, then the RNA for being connected with joint is inverted with SuperScriptII reverse transcription (Invitrogen products)
Record, synthesizes cDNA.Then, performing PCR amplification, amplification program are entered：98 DEG C of denaturations 30s, 98 DEG C of degeneration 10s, 60 DEG C of annealing 30s,
Thus 72 DEG C of extension 15s, 14 circulations, 72 DEG C of extension 8min build library.Finally, product utilization Illumina sequencings are extended
Platform carries out high-flux sequence.Joint sequence, the two ends low quality being sequenced in the initial data for producing is filtered using perl script
Sequence (sQ<=5 base number accounts for the sequence of more than the 50% of whole piece reads sequence, the ratio of N more than 10%, polyA/T/
G/C sequences).
SRNA valid data after screened by length compare people with reference on genome, analyze
Distribution and expression of the sRNAs in reference gene group, the sequence in comparison is compared with miRBase sequences, obtains
MiRNA information, while removing rRNA, tRNA, snRNA, snoRNA as far as possible.EBOV the infected (n is drawn with reference to sample information
=differential expression miRNA 12) compared with non-EBOV the infected (n=3), further by correlation analysiss, has found and EBOV
The related miRNA of virus infection.As a result show, belong to 5 miRNA (hsa- in 1 miRNA family (hsa-let-7 families)
Let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p and hsa-let-7f-5p), they
(p is remarkably decreased relative to expression in non-EBOV infection Healthy Peoples in EBOV the infected<0.01, differential expression multiple>4), and
Their target gene significantly increases (p accordingly<0.0001, differential expression multiple>3), concrete outcome is as shown in table 3, table 4.
Hsa-let-7 families miRNAs can regulate and control immunne response correlation molecule IL6, IGDCC3, hepatic injury correlation molecule CHRD, cell
Dead correlation molecule DPP6, FASLG, cell cycle and development correlation molecule E2F5, E2F6, MAB21L3, MEIS3, tissue repair
The gene expression of correlation molecule LIN28 etc., these results show 5 miRNA (hsa-let-7a- in hsa-let-7 families
5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p and hsa-let-7f-5p) and its target gene
(MAB21L3, MEIS3, DPP6, IGDCC3, CHRD, FASLG, LIN28, E2F5, IL6 and E2F6) can be used as biomolecule mark
Know, for the clinical diagnosises of EBOV the infected, it is also possible to as biological target molecule, for the design of anti-EBOV infection medicines.
Wherein, MAB21L3, MEIS3, DPP6, IGDCC3, CHRD, FASLG, LIN28, E2F5, IL6 and E2F6 are
The target base of hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p and hsa-let-7f-5p
Cause.
In actual applications, can be by comparing 5 miRNA (hsa-let-7a-5p, hsa- in hsa-let-7 families
Let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p and hsa-let-7f-5p) and its target gene (MAB21L3,
MEIS3, DPP6, IGDCC3, CHRD, FASLG, LIN28, E2F5, IL6 and E2F6) in object to be measured and non-EBOV the infected's blood
Expression in liquid is judging whether object to be measured is EBOV the infected.Specifically, the judgement mark for being obtained according to the above results
It is accurate as follows：As object to be measured hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p and
In hsa-let-7f-5p the expression of at least one less than the corresponding molecule of non-EBOV the infected 1/4 or MAB21L3,
In MEIS3, DPP6, IGDCC3, CHRD, FASLG, LIN28, E2F5, IL6 and E2F6, the expression of at least one is higher than non-
3 times of the corresponding molecule of EBOV the infected, the doubtful EBOV the infected of the object to be measured；The such as hsa-let-7a-5p of object to be measured,
The expression of hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p and hsa-let-7f-5p is not less than non-
1/4 and MAB21L3, MEIS3, DPP6, IGDCC3, CHRD, FASLG, LIN28, E2F5, IL6 of the corresponding molecule of EBOV the infected
3 times of non-EBOV the infected corresponding molecule are not higher than with the expression of E2F6, the object to be measured is non-EBOV the infected.
Table 3, the miRNAs for participating in EBOV infection damage regulation and control
Note：Tables of 5 miRNA of hsa-let-7 families in EBOV the infected and non-EBOV the infecteds is listed in table 3
Up to level (median TPM values) and Variant statistical analysis result (P values).
Table 4, hsa-let-7 families miRNA target gene in EBOV the infected differential expression
Note：The target gene of hsa-let-7 families miRNA is listed in table 4 in EBOV the infected and non-EBOV the infecteds
Expression (median FKPM values) and Variant statistical analysis result (P values).Wherein, MAB21L3 is mab-21-like 3
Abbreviation；Abbreviations of the MEIS3 for Meis homeobox 3；Abbreviations of the DPP6 for dipeptidyl peptidase like 6；
IGDCC3 be immunoglobulin superfamily, DCC subclass, the abbreviation of member 3；CHRD is chordin
Abbreviation；Abbreviations of the FASLG for Fas ligand；Abbreviations of the LIN28 for lin-28 homolog；E2F5 is E2F
The abbreviation of transcription factor 5；Abbreviations of the IL6 for interleukin 6；E2F6 is E2F transcription
The abbreviation of factor 6.
<110>Inst. of Epidemiology and Microbiology, Academy of Military Medical Sciences, PL
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 19
<212> DNA
<213>Artificial sequence
<220>
<223>
<400> 1
cgggcgcaac ataggaagt 19
<210> 2
<211> 20
<212> DNA
<213>Artificial sequence
<220>
<223>
<400> 2
cttctaggcg cagcacgaat 20
<210> 3
<211> 22
<212> DNA
<213>Artificial sequence
<220>
<223>
<400> 3
gtcaactgtt agccacgcag at 22
<210> 4
<211> 22
<212> DNA
<213>Artificial sequence
<220>
<223>
<400> 4
aaccaggctg tgacacttgt ct 22
Claims (9)
1. following R1)-R4) in arbitrary application：
R1) G1 is preparing treatment and/or is preventing the application in EBOV infection products as target spot；
R2) G1 is being treated and/or is being prevented the application in EBOV infection as target spot；
R3) detect application of the system of the G1 expressions in diagnosis or auxiliary diagnosis EBOV infection product is prepared；
R4) detect application of the system of the G1 expressions in diagnosis or the infection of auxiliary diagnosis EBOV；
The G1 is TRAF2 genes, TP53 genes, CASP9 genes, RIPK3 genes, CASP7 genes, CIAPIN1 genes, TNF
Gene, BAX genes, CASP6 genes, TYRO3 genes, MSR1 genes, MARCO genes, HAVCR1 genes, IRS1 genes,
LRSAM1 genes, TPCN2 genes, TPCN1 genes, ULK1 genes, AKT2 genes, MTOR genes, CASP8 genes and/or LAMP2
Gene.
2. application according to claim 1, it is characterised in that：The system of the detection G1 expressions is the detection G1
Reagent and/or instrument needed for expression.
3. following M1)-M4) in arbitrary application：
M1) P1 is preparing treatment and/or is preventing the application in EBOV infection products as target spot；
M2) P1 is being treated and/or is being prevented the application in EBOV infection as target spot；
M3) detect application of the system of the P1 contents in diagnosis or auxiliary diagnosis EBOV infection product is prepared；
M4) detect application of the system of the P1 contents in diagnosis or the infection of auxiliary diagnosis EBOV；
The P1 be TRAF2, TP53, CASP9, RIPK3, CASP7, CIAPIN1, TNF, BAX, CASP6, TYRO3, MSR1,
MARCO, HAVCR1, IRS1, LRSAM1, TPCN2, TPCN1, ULK1, AKT2, MTOR, CASP8 and/or LAMP2 protein.
4. application according to claim 3, it is characterised in that：Detect the system of the P1 contents to detect the P1 contents
Required reagent and/or instrument.
5. following N1)-N4) in arbitrary application：
N1) using G1 as system used in the diagnosis of EBOV infection marks or auxiliary diagnosis EBOV infection method following
A1 the application in) or a2)：
A1 diagnosis or auxiliary diagnosis EBOV infection product) are prepared；
A2) diagnosis or the infection of auxiliary diagnosis EBOV；
The G1 is TRAF2 genes, TP53 genes, CASP9 genes, RIPK3 genes, CASP7 genes, CIAPIN1 genes, TNF
Gene, BAX genes, CASP6 genes, TYRO3 genes, MSR1 genes, MARCO genes, HAVCR1 genes, IRS1 genes,
LRSAM1 genes, TPCN2 genes, TPCN1 genes, ULK1 genes, AKT2 genes, MTOR genes, CASP8 genes and/or LAMP2
Gene；
N2) using P1 as system used in the diagnosis of EBOV infection marks or auxiliary diagnosis EBOV infection method above-mentioned
A1 the application in) or a2)；
The P1 be TRAF2, TP53, CASP9, RIPK3, CASP7, CIAPIN1, TNF, BAX, CASP6, TYRO3, MSR1,
MARCO, HAVCR1, IRS1, LRSAM1, TPCN2, TPCN1, ULK1, AKT2, MTOR, CASP8 and/or LAMP2 protein；
N3) using the G1 as EBOV infect mark in above-mentioned a1) or a2) in application；
N4) using the P1 as EBOV infect mark in above-mentioned a1) or a2) in application.
6. following W1) or product W2)：
W1 EBOV infection products) are treated and/or prevent, with G1 as target spot；
The G1 is TRAF2 genes, TP53 genes, CASP9 genes, RIPK3 genes, CASP7 genes, CIAPIN1 genes, TNF
Gene, BAX genes, CASP6 genes, TYRO3 genes, MSR1 genes, MARCO genes, HAVCR1 genes, IRS1 genes,
LRSAM1 genes, TPCN2 genes, TPCN1 genes, ULK1 genes, AKT2 genes, MTOR genes, CASP8 genes and/or LAMP2
Gene；
W2 EBOV infection products) are treated and/or prevent, with P1 as target spot；
The P1 be TRAF2, TP53, CASP9, RIPK3, CASP7, CIAPIN1, TNF, BAX, CASP6, TYRO3, MSR1,
MARCO, HAVCR1, IRS1, LRSAM1, TPCN2, TPCN1, ULK1, AKT2, MTOR, CASP8 and/or LAMP2 protein.
7. following X1) or product X2)：
X1) diagnosis or auxiliary diagnosis EBOV infection product, are the system for detecting G1 expressions；
The G1 is TRAF2 genes, TP53 genes, CASP9 genes, RIPK3 genes, CASP7 genes, CIAPIN1 genes, TNF
Gene, BAX genes, CASP6 genes, TYRO3 genes, MSR1 genes, MARCO genes, HAVCR1 genes, IRS1 genes,
LRSAM1 genes, TPCN2 genes, TPCN1 genes, ULK1 genes, AKT2 genes, MTOR genes, CASP8 genes and/or LAMP2
Gene；
X2) diagnosis or auxiliary diagnosis EBOV infection product, are the system for detecting P1 contents；
The P1 be TRAF2, TP53, CASP9, RIPK3, CASP7, CIAPIN1, TNF, BAX, CASP6, TYRO3, MSR1,
MARCO, HAVCR1, IRS1, LRSAM1, TPCN2, TPCN1, ULK1, AKT2, MTOR, CASP8 and/or LAMP2 protein.
8. according to arbitrary application or product described in claim 6 or 7 in claim 1-5, it is characterised in that：The G1 tables
Up to the expression that level is G1 described in blood；The P1 contents are the content of P1 described in blood.
The construction method of 9.EBOV infection relevant molecular characteristics spectrums, including：Respectively to EBOV infected groups and non-EBOV infected groups blood
RNA or protein in liquid carries out quantitative analyses, obtains EBOV virus loads relevant molecular characteristics spectrum according to analysis result；It is described
EBOV virus loads relevant molecular characteristics spectrum is G1 or P1；
The G1 is TRAF2 genes, TP53 genes, CASP9 genes, RIPK3 genes, CASP7 genes, CIAPIN1 genes, TNF
Gene, BAX genes, CASP6 genes, TYRO3 genes, MSR1 genes, MARCO genes, HAVCR1 genes, IRS1 genes,
LRSAM1 genes, TPCN2 genes, TPCN1 genes, ULK1 genes, AKT2 genes, MTOR genes, CASP8 genes and/or LAMP2
Gene；
The P1 be TRAF2, TP53, CASP9, RIPK3, CASP7, CIAPIN1, TNF, BAX, CASP6, TYRO3, MSR1,
MARCO, HAVCR1, IRS1, LRSAM1, TPCN2, TPCN1, ULK1, AKT2, MTOR, CASP8 and/or LAMP2 protein.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611117710.8A CN106591446A (en) | 2016-12-07 | 2016-12-07 | Application of cellular pathway regulation molecules as drug target and to EBOV (Ebola virus) infection diagnosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611117710.8A CN106591446A (en) | 2016-12-07 | 2016-12-07 | Application of cellular pathway regulation molecules as drug target and to EBOV (Ebola virus) infection diagnosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106591446A true CN106591446A (en) | 2017-04-26 |
Family
ID=58596029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611117710.8A Pending CN106591446A (en) | 2016-12-07 | 2016-12-07 | Application of cellular pathway regulation molecules as drug target and to EBOV (Ebola virus) infection diagnosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106591446A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1323223A (en) * | 1998-10-09 | 2001-11-21 | 拜奥根有限公司 | Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway |
-
2016
- 2016-12-07 CN CN201611117710.8A patent/CN106591446A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1323223A (en) * | 1998-10-09 | 2001-11-21 | 拜奥根有限公司 | Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway |
Non-Patent Citations (3)
| Title |
|---|
| ANITA K MCELROY等: "Biomarkers for understanding Ebola virus disease", 《BIOMARK MED》 * |
| JASON KINDRACHUK等: "Ebola Virus Modulates Transforming Growth Factor β Signaling and Cellular Markers of Mesenchyme-Like Transition in Hepatocytes", 《JOURNAL OF VIROLOGY》 * |
| S.BAIZE等: "Inflammatory responses in Ebola virus-infected patients", 《CLIN EXP IMMUNOL》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9125923B2 (en) | Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy | |
| Wang et al. | Comparative miRNA expression profiles in individuals with latent and active tuberculosis | |
| Zhao et al. | Changes in microRNA expression induced by rabies virus infection in mouse brains | |
| CN110423811A (en) | Sepsis diagnosis marker | |
| CN106544440A (en) | The application of 7 family miRNA of hsa let and its target gene in EBOV Infect And Diagnoses and treatment | |
| CN107177676A (en) | Long-chain non-coding RNA NONHSAT113026 is used for the purposes of Diagnosis of Renal Cell Carcinoma molecular marker | |
| CN106591446A (en) | Application of cellular pathway regulation molecules as drug target and to EBOV (Ebola virus) infection diagnosis | |
| CN103911439A (en) | Analyzing method and application of differential expression gene of systemic lupus erythematosus hydroxymethylation status | |
| CN110408692A (en) | Marker of the molecule as diagnosis of sepsis disease in blood | |
| CN110475872B (en) | Detection method | |
| WO2023105295A2 (en) | Urine mirna marker for renal cancer diagnosis, diagnostic reagent and kit | |
| Liu et al. | Investigating the change in gene expression profile of blood mononuclear cells post-laparoscopic sleeve gastrectomy in Chinese obese patients | |
| CN109022570A (en) | Application of the non-coding RNA as sepsis diagnosis marker | |
| CN109609649B (en) | A lncRNA for rectal adenocarcinoma diagnosis and treatment | |
| CN109022572A (en) | LOC101927627 and its application as sepsis diagnosis marker | |
| CN106544448A (en) | The cytokine related to clinical prognosis and application in EBOV infected patient blood | |
| CN106544441A (en) | The related mark gene of Ebola virus infection and application | |
| JP2024504062A (en) | chromosome interactions | |
| CN106636464A (en) | Characteristic miRNAs in Ebola virus infected blood and application of characteristic miRNAs | |
| CN110408693A (en) | The new application of LOC105373033 | |
| CN109022571A (en) | Purposes of the LOC105369645 as sepsis diagnosis marker | |
| CN109797215A (en) | Marker is used in major depressive disorder diagnosis | |
| CN104711338A (en) | Use of miR-24 as reference gene of blood plasma/serum miRNA detection | |
| JP7242081B2 (en) | Methods for detecting small RNA | |
| CN108728542A (en) | Detect the preparation and its application process of long-chain non-coding RNA BC200 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170426 |